AlphAIAlphAI — Financial news for AI agents
investing.comOCT 142 min read$LQDA

Needham cuts Liquidia stock price target on settlement costs

Needham reduced Liquidia's (LQDA) price target to $58 from $72, maintaining a Buy rating after a $380.7M settlement with United Therapeutics. LQDA reported Q3 2026 Yutrepia sales of $222.7M, exceeding estimates, with a 92.5% gross margin. Analysts have mixed views on LQDA's outlook due to legal and operational challenges.

Original reporting
investing.com
Published Oct 14, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 12:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$LQDA
Bearish
high confidence
Mentioned
$LQDA
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$LQDABearishMed
01

Why it matters

The settlement removes legal uncertainty but imposes a sizable cash outflow, prompting analysts to lower price targets.

02

Market read

Analyst target revisions and settlement details provide fresh material for traders evaluating LQDA's near-term risk/reward.

03

What to watch

Cash balance of $396M provides runway; strong gross margins may mitigate the impact of the settlement payment.

Relevance 8/10Novelty 8/10Timing: today

Background

Liquidia Technologies settled a patent dispute with United Therapeutics, agreeing to pay $380.7M and keep its Yutrepia product on the market.

Company-level read

Ticker impact

$LQDABearishHigh confidence
Context

Needham lowered LQDA price target to $58 after the settlement with United Therapeutics involving a $380.7M payment.

Expected impact

likely downward pressure as investors price in the settlement payment

Evidence & confidence

The settlement removes legal uncertainty but imposes a large cash outflow, prompting analysts to trim valuations.

Market effects

Sector

Biotech sector may see heightened scrutiny on litigation risk, affecting peers with similar pipelines.

Regional

U.S. biotech stocks could face modest sell pressure amid broader risk reassessment.

Global

Limited to investors tracking U.S. biotech and litigation outcomes.

Counterpoint

What could challenge this read

The settlement clears a legal hurdle, allowing the company to focus on product rollout, which could support upside if execution succeeds.

Key entities

  • Company
    Liquidia Technologies

    Biotech firm developing inhaled therapies.

  • Company
    United Therapeutics

    Partner in the settlement agreement.

Read at source← All news

StoryLiquidia settles all litigation with United Therapeutics

Also covered by

4 outlets

Related articles

OCT 14
$LQDAMed

LifeSci Capital Upgrades Liquidia (LQDA) to Outperform Following

LifeSci Capital upgraded Liquidia (LQDA) to Outperform with a $59 price target, citing a recent settlement with United Therapeutics that resolved all outstanding lawsuits. LQDA is trading at $26.81, which is 90.6% below its GF Value™ of $285.95, indicating potential undervaluation. The company's GF Score™ is 69, reflecting strong growth but weak profitability and valuation. Insiders have sold $230.5 million in shares over the past year, while two gurus hold positions in LQDA.

gurufocus.com2 min